CARE(CARE)
CARE
Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.
Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.
| Metric | FY2026E | FY2027E | FY2028E | FY2029E |
|---|---|---|---|---|
| Revenue Avg | $329M | $304M | $553M | $614M |
| Low | $323M | $299M | $542M | $603M |
| High | $335M | $310M | $563M | $626M |
| EBITDA Avg | $76M | $70M | $128M | $142M |
| Low | $75M | $69M | $126M | $140M |
| High | $78M | $72M | $130M | $145M |
| EBIT Avg | $65M | $61M | $110M | $122M |
| Low | $64M | $59M | $108M | $120M |
| High | $67M | $62M | $112M | $124M |
| Net Income Avg | $144M | $55M | $64M | $62M |
| Low | $141M | $55M | $62M | $60M |
| High | $148M | $58M | $65M | $64M |
| EPS Avg | $6.43 | $2.50 | $2.84 | $2.76 |
| Low | $6.27 | $2.44 | $2.77 | $2.69 |
| High | $6.59 | $2.56 | $2.91 | $2.83 |
| Analysts (Rev / EPS) | 1 / 1 | 1 / 3 | 1 / 1 | 1 / 1 |
| Metric | Q3 2026 | Q4 2026 | Q1 2027 | Q2 2027 | Q3 2027 | Q4 2027 |
|---|---|---|---|---|---|---|
| Revenue Avg | $47M | $49M | $49M | $50M | $52M | $53M |
| Low | $45M | $47M | $47M | $48M | $50M | $51M |
| High | $48M | $50M | $50M | $52M | $53M | $54M |
| EBITDA Avg | $11M | $11M | $11M | $12M | $12M | $12M |
| Low | $10M | $11M | $11M | $11M | $12M | $12M |
| High | $11M | $12M | $12M | $12M | $12M | $13M |
| EBIT Avg | $9M | $10M | $10M | $10M | $10M | $11M |
| Low | $9M | $9M | $9M | $10M | $10M | $10M |
| High | $10M | $10M | $10M | $10M | $11M | $11M |
| Net Income Avg | $12M | $12M | $13M | $14M | $15M | $15M |
| Low | $11M | $12M | $12M | $14M | $14M | $14M |
| High | $12M | $13M | $13M | $15M | $15M | $16M |
| EPS Avg | $0.53 | $0.56 | $0.59 | $0.66 | $0.69 | $0.69 |
| Low | $0.50 | $0.53 | $0.56 | $0.63 | $0.65 | $0.66 |
| High | $0.54 | $0.58 | $0.61 | $0.68 | $0.70 | $0.72 |
| Analysts (Rev / EPS) | 2 / 2 | 2 / 2 | 1 / 1 | 1 / 1 | 1 / 1 | 1 / 1 |